We are live on ! Find out more
WE

Wealth Effects Portfolio holdings

AUM $282M
1-Year Est. Return 62.81%
This Fund
S&P 500
This Quarter Est. Return
+3.77%
1 Year Est. Return
+62.81%
3 Year Est. Return
+160.11%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$282M
AUM Growth
-$3.93M
Cap. Flow
-$6.27M
Cap. Flow %
-2.23%
Top 10 Hldgs %
46%
Holding
230
New
13
Increased
66
Reduced
108
Closed
18

Top Buys

Rank Stock Value
1
AVDL
Avadel Pharmaceuticals
AVDL
+$1.34M
2
DVN icon
Devon Energy
DVN
+$744K
3
ESTC icon
Elastic
ESTC
+$539K
4
MU icon
Micron Technology
MU
+$513K
5
PLTR icon
Palantir
PLTR
+$449K

Top Sells

Rank Stock Value
1
NVO
Novo Nordisk
NVO
+$844K
2
EXP icon
Eagle Materials
EXP
+$808K
3
NVDA icon
NVIDIA
NVDA
+$712K
4
PI icon
Impinj
PI
+$675K
5
AAPL icon
Apple
AAPL
+$650K

Sector Composition

Rank Sector Weight
1 Technology 29.06%
2 Healthcare 15.37%
3 Communication Services 8.73%
4 Financials 7.38%
5 Consumer Discretionary 6.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LPTH icon
201
Lightpath Technologies
LPTH
$651M
$164K 0.06%
+46,500
New +$86.8K
INDI icon
202
indie Semiconductor
INDI
$801M
$141K 0.05%
34,800
-71,900
-67% -$295K
BCS icon
203
Barclays
BCS
$92.8B
$133K 0.05%
10,000
– –
MUJ icon
204
BlackRock MuniHoldings New Jersey Quality Fund
MUJ
$649M
$125K 0.04%
11,268
– –
CATX icon
205
Perspective Therapeutics
CATX
$335M
$121K 0.04%
38,000
+24,750
+187% +$202K
SCYX icon
206
SCYNEXIS
SCYX
$39.7M
$114K 0.04%
11,750
-1,000
-8% -$10.4K
AUTL
207
Autolus Therapeutics
AUTL
$378M
$101K 0.04%
42,800
-8,200
-16% -$27.7K
XAIR icon
208
Beyond Air
XAIR
$4.09M
$70.6K 0.03%
492
-83
-14% -$14.9K
AKBA icon
209
Akebia Therapeutics
AKBA
$343M
$60.8K 0.02%
32,000
+5,000
+19% +$8.68K
NCZ
210
Virtus Convertible & Income Fund II
NCZ
$290M
$49.8K 0.02%
3,975
+425
+12% +$5.4K
HYFM icon
211
Hydrofarm Holdings
HYFM
$3.19M
$28.1K 0.01%
4,850
+100
+2% +$653
CURI icon
212
CuriosityStream
CURI
$154M
$21.6K 0.01%
14,140
+1,026
+8% +$1.98K
ARM icon
213
Arm
ARM
$292B
– –
-4,200
Closed -$601K
BYRN icon
214
Byrna Technologies
BYRN
$73.1M
– –
-10,000
Closed -$170K
CCLD icon
215
CareCloud
CCLD
$97.7M
– –
-12,857
Closed -$33.9K
CI icon
216
Cigna
CI
$74.9B
– –
-689
Closed -$239K
CL icon
217
Colgate-Palmolive
CL
$73.1B
– –
-1,980
Closed -$206K
CSCO icon
218
Cisco
CSCO
$441B
– –
-3,906
Closed -$208K
DLHC icon
219
DLH Holdings
DLHC
$77M
– –
-12,500
Closed -$117K
FNF icon
220
Fidelity National Financial
FNF
$13.8B
– –
-3,848
Closed -$239K
FXH icon
221
First Trust Health Care AlphaDEX Fund
FXH
$1.01B
– –
-1,840
Closed -$206K
HMC icon
222
Honda
HMC
$36.7B
– –
-6,724
Closed -$213K
IEI icon
223
iShares 3-7 Year Treasury Bond ETF
IEI
$18.1B
– –
-2,266
Closed -$271K
MUB icon
224
iShares National Muni Bond ETF
MUB
$45.5B
– –
-2,975
Closed -$323K
NVO
225
Novo Nordisk
NVO
$222B
– –
-7,085
Closed -$844K
6 7 8
9
10

Similar funds

SIC
Samalin Investment Counsel Chappaqua, New York $282M AUM 16.72% 1-Year Est. Return
DRD
Dennis R. Delaney $282M AUM 16.32% 1-Year Est. Return
II
INCA Investments Miami, Florida $282M AUM 42.53% 1-Year Est. Return
3CP
3G Capital Partners New York $282M AUM 22.21% 1-Year Est. Return
MFG
Monte Financial Group Guilford, Connecticut $282M AUM 14.97% 1-Year Est. Return
TC
TAGStone Capital Charlotte, North Carolina $283M AUM 14.51% 1-Year Est. Return
UFAC
Urban Financial Advisory Corp Chicago, Illinois $283M AUM 13.45% 1-Year Est. Return
TPW
Tiller Private Wealth Bethlehem, Pennsylvania $281M AUM 16.29% 1-Year Est. Return

Wealth Effects's Q4 2024 Portfolio in Review

As of Q4 2024, Wealth Effects held 230 positions worth $282M, down 1.4% from $285M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Wealth Effects's Q4 2024 filing shows 13 new, 66 increased, 108 reduced and 18 closed positions. Its largest new stake was Palantir: 7,714 shares worth $583K. The largest sale was Novo Nordisk, an estimated $844K.

By sector, the portfolio is most concentrated in Technology at 29% of assets, up from 28% a quarter earlier, followed by Healthcare and Communication Services.

  • Wealth Effects's largest Q4 2024 buy was Palantir: 7,714 shares worth $583K.
  • Wealth Effects added most to Avadel Pharmaceuticals in Q4 2024, an estimated $1.34M increase.
  • Wealth Effects's biggest Q4 2024 reduction was Eagle Materials, cutting an estimated $808K.
  • Wealth Effects fully exited Novo Nordisk in Q4 2024, selling an estimated $844K.
  • Wealth Effects's ten largest holdings make up 46% of its $282M portfolio in Q4 2024.
  • Wealth Effects opened 13 new positions and closed 18 in Q4 2024.
  • Wealth Effects's portfolio value fell 1.4% quarter-over-quarter to $282M.

Based on Wealth Effects's 13F filing for Q4 2024, filed 22 Jan 2025.